The effect on oncology practices
What is a hazardous drug?
According to the National Institute for Occupational Safety and Health (NIOSH), hazardous drugs are those which exhibit one or more of the following characteristics:
- Teratogenicity or development toxicity
- Reproductive toxicity
- Organ toxicity at low doses
- Structure and toxicity profiles of new drugs that mimic existing drugs determined hazardous by the above criteria
How does USP <800> affect an oncology practice?
USP General Chapter <800> is anticipated to become official on Dec. 1, 2019. If your practice is just getting started or is well on its way to compliance, here are a few key areas on which you should focus:
- Designate a USP <800> Champion. This person will identify the hazardous drugs used in the practice and be responsible for implementing procedures and adhering to the standard.
- Document everything related to USP <800>. To comply your practice must develop processes and procedures specific to hazardous drug risk assessment, document all hazardous drug training for staff, develop a Hazard Communications Plan and more.
- Understand how hazardous drugs travel through your practice. From delivery to disposal, are compliance issues lurking?
- Learn the requirements for the chemotherapy mixing room and negative vs. positive pressure areas.